PAD Resource Center Editorial Programs

 
 
  • Do Neprilysin Inhibitors Have a Role in Patients With CKD? Dr Desai reviews the UK HARP-III trial, which compares the effects of sacubitril/valsartan and irbesartan on kidney function in people with CKD.
  • Urgent Surgical Procedures: Does It Matter Who Is On Call? Dr Lowenfels comments on a study that examined whether surgical experience contributed to the outcomes of patients requiring urgent procedures.
  • More Fluoroquinolone Safety Concerns How do the most recently identified safety issues affect fluoroquinolones' place in therapy?
  • ECG Challenge: Tired and Out of Control An older woman presents with hypertension and lightheadedness. What does her ECG show?
  • How to Know When It's Autoimmune Epilepsy A conversation between Drs Andrew Wilner and Batool Kirmani on the red flags your patient may have this difficult-to-diagnosis condition.
  • 10 Little Known Uses for Common, Everyday Drugs Drugs you probably prescribe at least weekly have some benefits that are little known.
  • Multiple Myeloma: Relapse-Ready   City of Hope oncologists discuss optimal choices for treating patients with relapsed disease and report on emerging options that are changing the field.
  • ACC/AHA 2018 Cholesterol Guideline: The New and the Old   Drs Michael Blaha and Salim Virani review key takeaways from the 2018 ACC/AHA updated cholesterol guideline, noting that much is new in management of patients with elevated lipids.
  • CV Risk Assessment: A Process, Not a Calculation   Tips on how to estimate, personalize, and reclassify patient risk in light of the new cholesterol guidelines. Dr Blaha walks through a typical patient case with guideline writer Dr Lloyd-Jones
  • CV Risk: Can Prescription Omega-3 REDUCE-IT?   Low-dose omega-3 flopped for CV risk reduction. Melissa Walton-Shirley, MD, dissects the REDUCE-IT trial from AHA, which used high-dose prescription EPA, with principal investigator, Deepak Bhatt, MD.
  • Managing Gout as a Systemic Disease   A study suggests that to reduce morbidity and mortality from hyperuricemia, it must be managed as a chronic disease.
  • AHA 2018Nothing Fishy: Triglyceride Lowering With High-Dose EPA   How do the findings from the REDUCE-IT trial square with prior data on triglycerides and CVD? Prof Armitage sees a pattern.
  • AHA 2018Lipid Lollapalooza at AHA 2018 The release of the 2018 cholesterol guidelines and a bunch of lipid-oriented trials made it a bountiful day at the American Heart Association meeting for Melissa Walton-Shirley, MD.
  • AHA 2018Pure Fish Oil Lowers CVD Risk Even If We Don’t Understand How REDUCE-IT found that high-dose purified omega-3 fish oil reduced CV events even if the drug didn’t work as expected. Evidence-based practice means we should embrace these results, says John Mandrola, MD.
  • What Cardiologists Should Know About Obesity   Cardiologist Seth Baum interviews obesity experts Drs Kahan and Apovian, who dispel the myth of the 'obesity paradox' and the 'metabolically healthy obese,' and any fears about treating this disease.
  • A History of Sexual Assault and Harassment? Why We Must Ask   The physical and mental sequelae of these past events can be affecting a patient's health.
  • Mandrola Previews AHA 2018 Among the highlights for the upcoming American Heart Association Scientific Sessions are studies on omega-3, inflammation, a potential EP breakthrough, and yoga. Not to mention new lipid guidelines.
  • Meta-analyses: 5 Things to Know Meta-analyses are on the rise, but they are only as good as the techniques that produce them. These tips help determine whether you're dealing with 'garbage in, garbage out' or a worthwhile study.
  • Death Certificates: Do We Always Know 'Cause of Death'? Getting cause of death right is important. But is it achievable?
  • Can Tight Blood Pressure Control Prevent Dementia?   Dr Richard Isaacson discusses recent results from the SPRINT MIND study exploring the link between blood pressure and dementia risk.